THE PROTOTYPICAL PSYCHEDELIC AGENT LSD PRODUCES RAPID ANTIDEPRESSANT EFFECTS VIA 5-HT2B RECEPTOR ACTIVATION
The International Journal of Neuropsychopharmacology February 12, 2025 Amel Bouloufa, Sarah Delcourte, Renaud Rovera et al.
Abstract Background Recent clinical trials reveal that serotonergic psychedelics, including the prototypical hallucinogen lysergic acid diethylamide (LSD), present a promising potential for treating psychiatric disorders, including treatment-resistant depression. LSD is a potent 5-HT receptors ligand endowed with high affinity for most of all 5-HT subtypes and is regularly used as a valuable...